Benefit the patient, manage the risk: A system goal

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 5, 2004, Pages 269-276

  Califf, Robert M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERIVASTATIN; DOFETILIDE; FIBRIC ACID DERIVATIVE; SOTALOL;

ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; FINANCIAL MANAGEMENT; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; NATIONAL HEALTH SERVICE; PHARMACEUTICAL CARE; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; REIMBURSEMENT; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; TORSADE DES POINTES;

CLINICAL TRIALS; DRUG APPROVAL; HUMANS; TECHNOLOGY, PHARMACEUTICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 2542640021     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.957     Document Type: Article

References (34)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997; 349: 1498-1504.
2. Manton KG. Mortality patterns in developed countries. Comp Soc Res 1984; 7: 259-286.
3. DeMets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: part I. Circulation 2002; 106: 746-751.
4. DeMets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: part II. Circulation 2002; 106: 880-886.
5. Califf RM, DeMets DL. Principles from clinical trials relevant to clinical practice: part I. Circulation 2002; 106: 1015-1021.
6. Califf RM, DeMets DL. Principles from clinical trials relevant to clinical practice: part II. Circulation 2002; 106: 1172-1175.
7. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-613.
8. Fleming TF, DeGruttola V, DeMets DL. Surrogate endpoints. AIDS Clin Rev 1997-98; 129-143.
9. Furberg CD, Psaty BM. Should evidence-based proof of drug efficacy be extrapolated to a 'class of agents'? Circulation 2003; 108: 2608-2610.
10. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-1667.
11. Poole-Wilson PA, Swedberg K, Cleland JG, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol European trial (COMET): randomised controlled trial. Lancet 2003; 362: 7-13.
12. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart Failure survival study ELITE II. Lancet 2000; 355: 1582-1587.
13. Dickstein K, Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 2002; 360: 752-760.
14. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. for the valsartan in acute myocardial infarction investigators. Valsartan, captopril or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
15. Dickstein K, What did we learn from the OPTIMAAL trial? What can we expect from VALIANT? Am Heart J 2003; 145: 754-757.
16. Califf RM, Peterson ED, Gibbons RJ, et al. Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol 2002; 40: 1895-1901.
17. Roe MT, Ohman EM, Pollack CV, Jr, et al. Changing the model of care for patients with acute coronary syndromes. Am Heart J 2003; 146: 605-612.
18. Ferguson TB, Jr, Peterson ED, Coombs LP, Society of Thoracic Surgeons and the National Cardiac Database et al. Use of continuous quality improvement to increase use of process measures in patients undergoing coronary artery bypass graft surgery: a randomized controlled trial. JAMA 2003; 290: 49-56.
19. Peterson ED, Parsons LS, Pollack C, Newby LK, Littrell KA. Variation in AMI care processes across 1085 US hospitals and its association with hospital mortality rates. Circulation 2002; 106(Suppl. 2): 11-722.
20. Tunis SR, Stryer DB, Clancy CM. Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA 2003; 290: 1624-1632.
21. Sung NS, Crowley WF, Jr, Genel M, et al. Central challenges facing the national clinical research enterprise. JAMA 2003; 289: 1278-1287.
22. Gross R, Strom BL. Toward improved adverse event/suspected adverse drug reaction reporting. Pharmacoepidemiol Drug Safe 2003; 12: 89-91.
23. Strom BL. Risk assessment of drugs, biologics and therapeutic devices: current and future issues. Pharmacoepidemiol Drug Safe 2003; 12: 653-662.
24. LaPointe NM, Kramer JM, Weinfurt KP, Califf RM. Practitioner acceptance of the dofetilide risk-management program. Pharmacotherapy 2002; 22: 1041-1046.
25. Curtis LH, Ostbye T, Sendersky V, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003; 114: 135-141.
26. Davidson MH. Controversy surrounding the safety of cerivastatin. Exp Opin Drug Saf 2002; 1: 207-212.
27. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-1690.
28. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999; 341: 857-865.
29. Al-Khatib SM, LaPointe NM, Curtis LH, et al. Outpatient prescribing of antiarrhythmic drugs from 1995 to 2000. Am J Cardiol 2003; 91: 91-94.
30. LaPointe NM, Al-Khatib SM, Kramer JM, Califf RM. Knowledge deficits related to the QT interval could affect patient safety, Ann Noninvasive Electrocardiol 2003; 8: 157-160.
31. Allen LaPointe NM, Chen A, Hammill B, DeLong E, Kramer JM, Califf RM. Evaluation of the dofetilide risk-management program. Am Heart J 2003; 146: 894-901.
32. LaPointe NM, Kramer JM, Weinfurt KP, Califf RM. Practitioner acceptance of the dofetilide risk-management program. Pharmacotherapy 2002; 22: 1041-1046.
33. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: part II. Circulation 2002; 106: 626-630.
34. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine: part I. Circulation 2002; 106: 516-520.